MX2023001540A - Vacunas contra el cancer y metodos de tratamiento que las utilizan. - Google Patents

Vacunas contra el cancer y metodos de tratamiento que las utilizan.

Info

Publication number
MX2023001540A
MX2023001540A MX2023001540A MX2023001540A MX2023001540A MX 2023001540 A MX2023001540 A MX 2023001540A MX 2023001540 A MX2023001540 A MX 2023001540A MX 2023001540 A MX2023001540 A MX 2023001540A MX 2023001540 A MX2023001540 A MX 2023001540A
Authority
MX
Mexico
Prior art keywords
methods
treatment
same
cancer vaccines
vaccine
Prior art date
Application number
MX2023001540A
Other languages
English (en)
Inventor
Jian Yan
Original Assignee
Inovio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inovio Pharmaceuticals Inc filed Critical Inovio Pharmaceuticals Inc
Publication of MX2023001540A publication Critical patent/MX2023001540A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001154Enzymes
    • A61K39/001157Telomerase or TERT [telomerase reverse transcriptase]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241Nucleotidyltransferases (2.7.7)
    • C12N9/1276RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y207/00Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07Nucleotidyltransferases (2.7.7)
    • C12Y207/07049RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55522Cytokines; Lymphokines; Interferons
    • A61K2039/55527Interleukins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/58Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invención proporciona una vacuna que comprende una molécula de ácido nucleico que codifica un antígeno de telomerasa transcriptasa inversa de perro (dTERT), así como métodos para utilizar la vacuna para inducir una respuesta inmunitaria contra TERT y para tratar cáncer en un mamífero.
MX2023001540A 2016-02-05 2018-08-03 Vacunas contra el cancer y metodos de tratamiento que las utilizan. MX2023001540A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662291601P 2016-02-05 2016-02-05

Publications (1)

Publication Number Publication Date
MX2023001540A true MX2023001540A (es) 2023-03-08

Family

ID=59500919

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018009506A MX2018009506A (es) 2016-02-05 2017-02-03 Vacunas contra el cáncer y métodos de tratamiento que las utilizan.
MX2023001540A MX2023001540A (es) 2016-02-05 2018-08-03 Vacunas contra el cancer y metodos de tratamiento que las utilizan.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018009506A MX2018009506A (es) 2016-02-05 2017-02-03 Vacunas contra el cáncer y métodos de tratamiento que las utilizan.

Country Status (10)

Country Link
US (3) US11007255B2 (es)
EP (1) EP3411122A4 (es)
JP (1) JP7123800B2 (es)
KR (1) KR20180108793A (es)
CN (2) CN108883312B (es)
AU (2) AU2017214656B2 (es)
BR (1) BR112018015893A2 (es)
CA (1) CA3013718C (es)
MX (2) MX2018009506A (es)
WO (1) WO2017136758A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3064890A1 (en) * 2017-05-26 2018-11-29 The Wistar Institute Of Anatomy And Biology Dtert vaccines and methods of treatment using the same
EP3703734A1 (en) 2017-10-31 2020-09-09 Pantarhei Bioscience B.V. Immunotherapeutic methods for treating and/or preventing lung cancer
EP3723798A4 (en) * 2017-12-13 2021-11-17 Inovio Pharmaceuticals, Inc. ANTI-BORIS CANCER VACCINES AND USES
WO2021259963A1 (en) 2020-06-23 2021-12-30 Pandora Endocrine Innovation B.V. Immunization against wnt4 for treatment and prophylaxis of breast cancer
EP4419122A1 (en) 2021-10-19 2024-08-28 Sciencemed Spólka Z Ograniczona Odpowiedzialnoscia Male contraception
WO2023237726A1 (en) 2022-06-10 2023-12-14 Pantarhei Oncology B.V. An intracellular tumor-specific variant of human zona pellucida glycoprotein 3 and nucleic acids coding therefor for use in the treatment of cancer

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
NZ262582A (en) 1993-01-26 1997-10-24 David B Weiner Compositions and methods for delivery of genetic material
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
NL9401820A (nl) 1994-11-02 1996-06-03 Meyn Maschf Inrichting voor het bewerken van aan zijn poten opgehangen gevogelte.
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
DE69835761T2 (de) 1997-04-03 2007-09-13 Electrofect As. Verfahren zum verabreichen von pharmazeutischen präparaten und nukleinsäuren an den skelettmuskel
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
CZ299473B6 (cs) 1997-06-30 2008-08-06 Rhone-Poulenc Rorer S. A. Nukleová kyselina a elektrické pole jako sdruženýprodukt pro prenos nukleové kyseliny do bunek prícne pruhovaného svalstva
EP2428249B1 (en) 1998-07-13 2015-10-07 Inovio Pharmaceuticals, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
US20040175727A1 (en) 2002-11-04 2004-09-09 Advisys, Inc. Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells
CA2567324C (en) 2003-05-30 2012-01-03 Advisys, Inc. Devices and methods for biomaterial production
CN105132439A (zh) * 2006-07-28 2015-12-09 宾夕法尼亚大学托管会 改进的疫苗及其使用方法
BRPI0719865A2 (pt) * 2006-10-12 2016-03-15 Angeletti P Ist Richerche Bio molécula de ácido nucleico, proteína de fusão purificada, vetor, célula hospedeira, processo para expressar uma proteína de fusão, e, método para tratar um paciente sofrendo de ou predisposto a um câncer
PT2066399T (pt) 2006-10-17 2019-01-11 Inovio Pharmaceuticals Inc Dispositivos de eletroporação e métodos de usar os mesmos para eletroporação de células em mamíferos
PT2153260T (pt) 2007-05-23 2017-04-24 Vgxi Inc Composição que compreende uma alta concentração de moléculas biologicamente ativas e processos de preparação da mesma
WO2013019603A2 (en) * 2011-07-29 2013-02-07 Inovio Pharmaceuticals, Inc. Linear expression cassettes and uses thereof
US11419925B2 (en) 2013-03-15 2022-08-23 The Trustees Of The University Of Pennsylvania Cancer vaccines and methods of treatment using the same
US10138488B2 (en) * 2013-03-28 2018-11-27 Invectys Cancer vaccine for dogs
US10398769B2 (en) * 2013-08-06 2019-09-03 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
CA3064890A1 (en) * 2017-05-26 2018-11-29 The Wistar Institute Of Anatomy And Biology Dtert vaccines and methods of treatment using the same

Also Published As

Publication number Publication date
MX2018009506A (es) 2019-05-06
CN108883312B (zh) 2024-04-09
BR112018015893A2 (pt) 2019-03-06
US11801288B2 (en) 2023-10-31
EP3411122A1 (en) 2018-12-12
WO2017136758A1 (en) 2017-08-10
US20190038729A1 (en) 2019-02-07
KR20180108793A (ko) 2018-10-04
AU2017214656B2 (en) 2022-08-25
AU2017214656A1 (en) 2018-08-30
CN118184761A (zh) 2024-06-14
EP3411122A4 (en) 2019-10-23
US20240082374A1 (en) 2024-03-14
US20210268084A1 (en) 2021-09-02
AU2022271441A1 (en) 2022-12-22
CN108883312A (zh) 2018-11-23
CA3013718A1 (en) 2017-08-10
CA3013718C (en) 2023-09-26
US11007255B2 (en) 2021-05-18
JP2019508403A (ja) 2019-03-28
JP7123800B2 (ja) 2022-08-23

Similar Documents

Publication Publication Date Title
MX2023001540A (es) Vacunas contra el cancer y metodos de tratamiento que las utilizan.
JOP20200192A1 (ar) أجسام مضادة لـ tigit
MX2021013837A (es) Enfoque de inmunoterapias de combinacion para el tratamiento del cancer.
PH12019500628A1 (en) Anti-cd27 antibodies
PH12018502112A1 (en) Anti-tim-3 antibodies and compositions
MX2023014569A (es) Anticuerpos anti-sirpa.
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
NZ739750A (en) Anti-tigit antibodies and methods of use
EA201800148A1 (ru) Оспенная вакцина для лечения рака
MX2017001406A (es) Agentes a base de flagelina y usos de los mismos, incluyendo vacunación efectiva.
WO2013106834A3 (en) Immunogenic wt-1 peptides and methods of use thereof
MX2018004598A (es) Cepas vacunales recombinantes de listeria y métodos para usar las mismas en la inmunoterapia contra el cáncer.
MX2017002862A (es) Nuevos anticuerpos anti-mfi2 y metodos de uso.
CL2017000625A1 (es) Composiciones de glicoconjugado inmunogénico/terapéutico y sus usos
MX2017011991A (es) Terapia virica con una combinacion de anticuerpos.
BR112017025533A2 (pt) método para tratar câncer em um paciente humano
UY36617A (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer
MX2020004376A (es) Uso de inhibidores de nox para el tratamiento de cancer.
PH12018501170A1 (en) Vaccination with mica/b alpha 3 domain for the treatment of cancer
MX2022009171A (es) Composiciones para el tratamiento de dermatitis atopica canina y sus usos.